Role of Bupropion Plus Naltrexone for the Management of Obesity
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Objective. The pharmacology, pharmacokinetics, efficacy, and safety of bupropion plus naltrexone for weight loss were reviewed. Data Sources. A MEDLINE search (1970 to November 2015) was conducted for English-language articles using specific MESH terms. Study Selection and Data Extraction. Published Phase 3 clinical trials with primary endpoints related to weight loss were included and critiqued in this review. Study Selection and Data Extraction. Five trials were retrieved and reviewed regarding the efficacy and safety of bupropion plus naltrexone among obese and overweight patients. Data Synthesis. Bupropion is a dopamine/norepinephrine reuptake inhibitor, and naltrexone is an opioid receptor antagonist. The combination of these agents has led to increased weight loss, compared to placebo, among overweight and obese patients with a body mass index (BMI) at or above 30 or BMI at or above 27 with a comorbid condition. The combination of bupropion and naltrexone can produce an average placebo-subtracted weight loss of 4.25% over 56 weeks. Gastrointestinal (ie, nausea, vomiting, constipation) and central nervous system adverse events (ie, headache, dizziness) were commonly reported, and there was a high dropout rate among participants. Conclusions. Bupropion plus naltrexone has demonstrated effective weight loss, in conjunction with lifestyle modifications, among overweight and obese patients with and without comorbidities. Bupropion plus naltrexone has not been studied among special patient populations, such as those with sleep apnea, osteoarthritis, or extreme BMIs. Additional clinical trials and postmarketing data will provide a better understanding of this medication for weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580 · cited 1×
“Obesity is recognized as a disease state by the American Medical Association and is a risk factor for the development of diabetes, cardiovascular diseases (ie, stroke, hypertension), osteoarthritis, and certain types of cancers.(2-5) It is important to educate and empower patients to modify their lifestyle habits.”
BackgroundActual Causes of Death in the United States, 2000
Mokdad, A. H. (2004) · JAMA · doi:10.1001/jama.291.10.1238 · Cited by 5,211
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
(1998) · PubMed · Cited by 2,737
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 1×
“It has a similar indication as other approved medications, such as lorcaserin and phentermine plus topiramate, and all are supported by the guidelines for pharmacologic interventions in obesity management.(8-12) The article reviews the clinical evidence of bupropion plus naltrexone for obesity management.”
BackgroundGadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 1×
“Due to blinding methods, it could be difficult to conduct a study between bupropion plus naltrexone and liraglutide.(24-30) To overcome blinding, dummy injections or oral formulations could be used to compare bupropion plus naltrexone to any dissimilar formulation.”
Backgroundon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Research works printed but not linked: 5
- 8. Contrave [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc, and La Jolla, CA: Orexigen Therapeutics, Inc; 2014. [Google Scholar]
- 13. Wellbutrin [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014. [Google Scholar]
- 14. Zyban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2015. [Google Scholar]
- 19. Naltrexone [package insert]. Sellersville, PA: Teva Pharmaceuticals, Inc; 2013. [Google Scholar]
- 32. O’Riordan M. LIGHT stopped: Contrave CVD safety study halted following premature release of data. Medscape News Alerts. http://www.medscape.com/viewarticle/844575. Published May 12, 2015. Accessed December 17, 2015. Articles from The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians are provided here courtesy of SAGE Publications
Cited by
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Metadata
- Authors
- Booth, K., & Clements, J. N.
- Affiliations
- Presbyterian College (US)
- Corresponding author
- Clements, Jennifer N.
- Venue
- Journal of Pharmacy Technology
- Publisher
- SAGE Publications
- Published
- 2016-01-11
- Volume
- 32
- Issue
- 3
- Pages
- 125-132
- ISSN
- 1549-4810 (ISSN-L)
- 8755-1225
- PMC
- PMC5998459
- OpenAlex
- W2341654874
- Semantic Scholar
- 8cbb2de03e8f09a44454469ff4ad7fc99fd141b6
- Cited by
- 13
- References
- 22
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 3 · 2017: 1
- FWCI
- 0.27
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Pharmacy Technology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- bupropion, naltrexone, combination pharmacotherapy, obesity, weight loss, opioid antagonists, pharmacokinetics, gastrointestinal adverse effects, central nervous system adverse events, lifestyle modification, overweight, comorbid obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of Bupropion Plus Naltrexone for the Management of Obesity. https://app.cochat.ai/papers/10.1177/8755122515624220
- The paper
- Booth, K., & Clements, J. N. (2016). Role of Bupropion Plus Naltrexone for the Management of Obesity. Journal of Pharmacy Technology. https://doi.org/10.1177/8755122515624220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.